I hope that the 125K of shares purchased by insiders put your mind to rest about the Phase Ib data. This will be very well received by the markets tomorrow. GL!
All is possible! I agree that it is strange that we have not heard anything, but not totally surprised. Management is running a company and not trying to manage a PPS.
Well I guess you know more than me, but i was not expecting interim data by then. Who knows what the impact of the halt has. Anyway, abstracts are due Dec 3rd, so not that far away. I am not going to count ESMO out till the 17th, but it does not look good.
I think this would be the next event - American Assoc for Cancer Research:
AACR Annual Meeting 2015
April 18-22, 2015
Pennsylvania Convention Center
Abstract Deadline: December 3, 2014
It may already be reflected in the PPS and that is why we did not get traction from the approval. We'll know by Sept 17. Good luck!
Its wrong. Go look at Roche's Q2 presentation for market presentation and countries that Herceptin SC is selling in. Its impressive and I only hoes that Mab SC does as well. Roche had a separate slide for it and that says something.
I can't answer that, but I would hope that the P2 trial could not have started without a review of the data, at that time and had to be looked at to get fast track designation. If IR is as bad as you claim, maybe there is still a glimmer of hope that HALO is presenting at ESMO, but I doubt it, at this point.
But HALO would know by now if it was presenting and should have already sent out a PR. Last year, the PR was sent out Sept 12. Zhu was the presenter.
Don't get me wrong, it is good long term news, but it is an approval of HyQvia that is hardly selling in Europe (who knows why). If we get new partners, or announced partnered drugs, then we have something more tangible. Also no PR on ESMO does not help matters,
In my experience, your response on investor e-mails is par for the course, except for the smallest of companies. I hope that they are spending their time more wisely, then answering e-mails like yours. Sorry for my honesty.
By year end, we could be in that neighborhood, but hopefully with the expectation of good data, SNGX is above $2. The SO will weigh on the PPS because of the low price, so it will be a delicate balance between the two.
I just looked through your posts and did not see your comment. I was interested in your logic. Anyway, all biotechs are down, but admittedly, we should not be one of them Lack of ESMO news is certainly weighing on the PPS.
Chris practically assured investors that it is in the bag and that we would hear in September. As I have said before, I would be shocked if we do not win it.
Makes sense. There is only a little less than 3.5 years to go and the strike price is $1.65. This management could do it :-) Heaven help us!
They had three sites and needed 40 patients. I believe you, but still surprised. Then, they should have said that which would have been acceptable, IMO. They pulled the study due to lack of interest at this time and the money was used to fund the other studies. The handling of SGX 203 is also mess. Who would have thought that SNGX would be trading down around $1.70, again. So much for the 2H catalysts.......unbelievable. I agree that Chris has to go to restore investor confidence. It will be interesting to see what the PPS sinks to now. Good luck to you!
There should not need the cash before the SGX 942 data and not initiate any actions that would cause this to occur. If mgt has a SO before the SGX 942 data, IMO it means the data is no good. This report is why we are falling on higher than usual volume. Investors are not dumb and see through their ruse.
Orbec was airbrushed out of the report and the Corporate presentation. Is that not the kiss of death for the study? At some point there will be a PR announcing this fact, but when?
It appears to me that the equity offering they are referring to would be a stock offering and not shares sold to Lincoln. It appears to me based upon the disclosures in the report that Griffin will be involved in the stock offering. Hopefully, the SGX 942 data is disclosed before the SO and it is positive. Although, not disclosed before, I knew SNGX was going to have to have a funding before the SGX 942 phase III trial would begin, but I was also counting on the 2H catalysts that for the most part did not occur. Good luck to all longs!